Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 3/20 | 0.53 |
| ▸ | AXL | P30530 | 3/20 | 0.48 |
| ▸ | MERTK | Q12866 | 3/20 | 0.48 |
| ▸ | TNK2 | Q07912 | 5/20 | 0.48 |
| ▸ | TYRO3 | Q06418 | 4/20 | 0.47 |
| ▸ | ACVRL1 | P37023 | 2/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | RICTOR | Q6R327 | 1/20 | 0.43 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.43 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 0.43 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | CCND1 | P24385 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL123014 | 0.87 | BTK (0.68) | BTKAXLMERTKTNK2TYRO3 | |
| SCHEMBL123477 | 0.82 | BTK (0.56) | BTKAXLMERTKTNK2ACVRL1 | |
| SCHEMBL168004 | 0.79 | BTK (0.52) | BTKAXLMERTKTNK2ACVRL1 | |
| SCHEMBL120431 | 0.73 | BTK (0.56) | BTKTNK2ACVRL1PIK3CD | |
| SCHEMBL123466 | 0.72 | BTK (0.70) | BTKAXLMERTKTNK2PIK3CD | |
| SCHEMBL14312934 | 0.72 | MERTK (0.58) | AXLMERTKTYRO3PIK3CD | |
| SCHEMBL31630266 | 0.72 | AXL (0.49) | AXLMERTKTYRO3ACVRL1MTOR | |
| SCHEMBL120433 | 0.72 | BTK (0.66) | BTKTNK2 | |
| SCHEMBL120432 | 0.72 | BTK (0.66) | BTKTNK2 | |
| SCHEMBL122566 | 0.71 | BTK (0.94) | BTKTNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765754-B2 | Pyrrolotriazine compounds | LOCUS PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20120232054-A1 | PYRROLOTRIAZINE COMPOUNDS | LOCUS PHARMACEUTICALS, INC. (US) | 2012-09-13 | — | — | US | disclosed |
| EP-2424368-A1 | PYRROLOTRIAZINE COMPOUNDS | Locus Pharmaceuticals, Inc. (US) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010126960-A1 | PYRROLOTRIAZINE COMPOUNDS | LOCUS PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232054-A1 | PYRROLOTRIAZINE COMPOUNDS | BTK, SYK, ZAP70 | BTK 1/4885AXL 633/4885MERTK 600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.